Earnings summaries and quarterly performance for Jazz Pharmaceuticals.
Executive leadership at Jazz Pharmaceuticals.
Renee Gala
Detailed
President and Chief Executive Officer
CEO
LH
Liz Henderson
Detailed
Senior Vice President, Technical Operations
NP
Neena Patil
Detailed
Executive Vice President and Chief Legal Officer
PC
Patricia Carr
Detailed
Senior Vice President, Chief Accounting Officer
PJ
Philip Johnson
Detailed
Executive Vice President and Chief Financial Officer
RI
Robert Iannone
Detailed
Executive Vice President, Global Head of Research & Development and Chief Medical Officer
SP
Samantha Pearce
Detailed
Executive Vice President, Chief Commercial Officer
Board of directors at Jazz Pharmaceuticals.
AO
Anne O’Riordan
Detailed
Director
BC
Bruce Cozadd
Detailed
Chair of the Board
HA
Heather Ann McSharry
Detailed
Director
JC
Jennifer Cook
Detailed
Director
KO
Kenneth O’Keefe
Detailed
Director
LH
Laura Hamill
Detailed
Director
MS
Mark Smith
Detailed
Director
NR
Norbert Riedel
Detailed
Director
PE
Patrick Enright
Detailed
Director
PK
Patrick Kennedy
Detailed
Director
RW
Rick Winningham
Detailed
Lead Independent Director
SM
Seamus Mulligan
Detailed
Director
TL
Ted Love
Detailed
Director
Research analysts who have asked questions during Jazz Pharmaceuticals earnings calls.
Ami Fadia
Needham & Company, LLC
6 questions for JAZZ
Also covers: ACAD, ALKS, AVDL +10 more
David Amsellem
Piper Sandler Companies
6 questions for JAZZ
Also covers: ABBV, ALKS, AMGN +27 more
Gary Nachman
Raymond James
6 questions for JAZZ
Also covers: ABBV, ACHV, ADMA +9 more
AN
Andrea Newkirk
Goldman Sachs
5 questions for JAZZ
Also covers: ABCL, ALKS, ARWR +9 more
Annabel Samimy
Stifel Financial Corp.
5 questions for JAZZ
Also covers: ALT, APLS, CARA +14 more
Gregory Renza
RBC Capital Markets
5 questions for JAZZ
Also covers: ACAD, ADCT, AGIO +12 more
Jason Gerberry
Bank of America Merrill Lynch
5 questions for JAZZ
Also covers: ALKS, AMPH, ARWR +21 more
JF
Jessica Fye
JPMorgan Chase & Co.
5 questions for JAZZ
Also covers: ALKS, ALNY, AMRN +23 more
JL
Joon Lee
Truist Securities
5 questions for JAZZ
Also covers: ADVM, AXSM, CNM +14 more
MG
Marc Goodman
Leerink Partners
5 questions for JAZZ
Also covers: ACAD, ALDX, ALKS +14 more
Mohit Bansal
Wells Fargo & Company
5 questions for JAZZ
Also covers: ABBV, AMGN, BMRN +16 more
Joseph Thome
TD Cowen
4 questions for JAZZ
Also covers: ALKS, AMLX, ARDX +12 more
Akash Tewari
Jefferies
3 questions for JAZZ
Also covers: ALKS, APLS, ARGX +15 more
AL
Amy Li
Jefferies Financial Group Inc.
3 questions for JAZZ
Also covers: ARGX, IRWD, MDGL
JH
Jeff Hung
Morgan Stanley
2 questions for JAZZ
Also covers: ACAD, ALEC, BHVN +10 more
TL
Troy Langford
TD Cowen
2 questions for JAZZ
Also covers: ALKS, AXSM, NTLA
AV
Ashwani Verma
UBS Group AG
1 question for JAZZ
Also covers: ACAD, ALKS, ALVO +12 more
CD
Charles Duncan
Cantor Fitzgerald & Co.
1 question for JAZZ
Also covers: ACAD, ALKS, ATAI +12 more
DH
David Hoang
Citigroup
1 question for JAZZ
Also covers: ACAD, ALKS, AVDL +8 more
JB
Joel Beatty
Baird
1 question for JAZZ
Also covers: ACAD, ALKS, AMLX +11 more
Michael Riad
Morgan Stanley
1 question for JAZZ
Also covers: ACAD, ALEC, ITCI +3 more
Sean Laaman
Morgan Stanley & Co.
1 question for JAZZ
Also covers: ACAD, ARGX, AXSM +8 more
Recent press releases and 8-K filings for JAZZ.
Jazz Pharmaceuticals' Collaboration with Iambic Therapeutics Highlighted at J.P. Morgan Conference
JAZZ
New Projects/Investments
- Iambic Therapeutics is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT.
- The presentation will highlight a research collaboration and drug supply agreement with Jazz Pharmaceuticals to evaluate IAM1363 in combination with zanidatamab for HER2-positive breast cancer.
- IAM1363, Iambic’s lead AI-designed drug candidate, has demonstrated anti-tumor activity across HER2-wild-type and HER2-mutated cancers and a favorable safety profile in Phase 1/1b data.
- Iambic also raised an oversubscribed financing exceeding $100 million to support clinical expansion and continued platform growth.
Dec 16, 2025, 1:00 PM
Jazz Pharmaceuticals to Present Positive Ziihera Trial Results at ASCO GI 2026
JAZZ
New Projects/Investments
- Jazz Pharmaceuticals will present positive Phase 3 HERIZON-GEA-01 trial results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) from January 8-10, 2026.
- The trial demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) for Ziihera combinations compared to the control arm.
- An investor webcast will be hosted on Friday, January 9, 2026, at 6:30 a.m. PT/ 9:30 a.m. ET to review the Ziihera data presented at the meeting.
Dec 2, 2025, 9:05 PM
Jazz Pharmaceuticals Reports Record Q3 2025 Revenues and Provides Business Updates
JAZZ
Guidance Update
Product Launch
M&A
- Jazz Pharmaceuticals reported record revenues of $1.13 billion in Q3 2025, an increase of approximately 7%, and subsequently raised its ANI and EPS guidance. The company also recognized a $206 million deferred tax asset related to the Chimerix acquisition and finished the quarter with $2 billion in cash and investments.
- Key products Epidiolex and Xywav demonstrated strong growth, with Epidiolex on track to achieve blockbuster status. Xywav's growth was primarily driven by the idiopathic hypersomnia (IH) indication, with approximately 325 new patient additions in IH in the most recent quarter.
- Midaso, acquired through Chimerix, had a strong initial launch, generating $11 million in net sales in Q3 2025 after only a few weeks on the market, serving about 200 patients, and is projected to reach peak sales exceeding $500 million.
- The company announced positive data for zanidatamab in the first-line GEA trial, showing statistically significant and clinically meaningful progression-free survival, and received approval for Zepzelca's first-line maintenance indication. Jazz Pharmaceuticals plans to continue external investments in corporate development, focusing on oncology and epilepsy.
Dec 2, 2025, 2:45 PM
Jazz Pharmaceuticals Discusses Strong Q3 2025 Performance and Product Pipeline
JAZZ
Guidance Update
Product Launch
New Projects/Investments
- Jazz Pharmaceuticals reported record revenues of $1.13 billion in Q3 2025, an increase of approximately 7%, and recognized a $206 million deferred tax asset related to the Chimerix acquisition, leading to updated ANI and EPS guidance.
- The company announced strong data from the first-line GEA trial for zanidatamab, showing statistically significant and clinically meaningful progression-free survival for the doublet and both PFS and overall survival for the triplet.
- The initial launch of Midaso (from the Chimerix acquisition) generated $11 million in net sales in Q3 2025 from approximately 200 patients in just a few weeks, exceeding expectations and with peak sales potential north of $500 million.
- Epidiolex is on track to achieve blockbuster status, while Xywav continues strong growth, primarily from the idiopathic hypersomnia (IH) indication, though generic versions of Xyrem are anticipated in 2026 which could create headwinds. Jazz finished Q3 2025 with about $2 billion in cash and investments.
Dec 2, 2025, 2:45 PM
Jazz Pharmaceuticals Discusses Strong Q3 2025 Performance and Strategic Growth Initiatives
JAZZ
Guidance Update
Product Launch
New Projects/Investments
- Jazz Pharmaceuticals reported record revenues of $1.13 billion in Q3 2025, an increase of 7%, driven by strong performance from Epidiolex and Xywav. This led to narrowed revenue guidance and increased ANI and EPS guidance.
- The company recognized a $206 million deferred tax asset related to the Chimerix acquisition and highlighted the strong initial launch of Modeso, which generated $11 million in net sales in 3Q 2025 from approximately 200 patients.
- Jazz announced strong results from the first-line GEA trial for zanidatamab, demonstrating statistically significant and clinically meaningful progression-free survival, with a strong trend towards overall survival benefit.
- Xywav continues to grow, primarily from idiopathic hypersomnia (IH), and Epidiolex is on track to achieve blockbuster status. The company ended Q3 2025 with approximately $2 billion in cash and investments.
Dec 2, 2025, 2:45 PM
Jazz Pharmaceuticals Reports Positive Phase 3 Results for Ziihera in HER2-Positive GEA
JAZZ
Product Launch
New Projects/Investments
- Jazz Pharmaceuticals announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
- Both Ziihera plus chemotherapy, and Ziihera plus the PD-1 inhibitor Tevimbra (tislelizumab) and chemotherapy, demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to the control arm.
- Ziihera plus tislelizumab and chemotherapy also showed clinically meaningful and statistically significant improvements in overall survival (OS), with Ziihera plus chemotherapy demonstrating a strong trend toward statistical significance for OS at the first interim analysis.
- The company plans to submit a supplemental Biologics License Application (sBLA) in the U.S. in the first half of 2026 for Ziihera in this indication.
Nov 17, 2025, 11:28 AM
Jazz Pharmaceuticals and Zymeworks Report Positive Phase 3 Trial Results for Ziihera
JAZZ
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Zymeworks and Jazz Pharmaceuticals announced positive Phase 3 trial results for their HER2-targeted bispecific antibody Ziihera (zanidatamab-hrii) as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The HERIZON-GEA-01 trial demonstrated statistically significant improvements in progression-free survival for both treatment regimens, with one combination also showing significant overall survival benefits.
- Following the announcement, Zymeworks' stock rose 59% and Jazz Pharmaceuticals' stock gained 31% in premarket trading.
- Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in the first half of 2026 to support Ziihera’s use as a first-line treatment, with an additional overall survival interim analysis expected in mid-2026.
- Ziihera is already approved in the U.S., Europe, and China for second-line biliary tract cancer.
Nov 17, 2025, 11:21 AM
Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive GEA
JAZZ
Product Launch
New Projects/Investments
- Jazz Pharmaceuticals announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
- Both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to the control arm.
- The combination of Ziihera, tislelizumab, and chemotherapy also showed statistically significant and clinically meaningful improvements in overall survival (OS), while Ziihera plus chemotherapy demonstrated a strong trend toward statistical significance for OS.
- The company plans to submit a supplemental Biologics License Application (sBLA) in the U.S. in the first half of 2026, aiming for Ziihera to become the new standard of care for this indication.
Nov 17, 2025, 11:00 AM
Jazz Pharmaceuticals to Present New Clinical and Translational Data for Modeyso and JZP3507 at SNO 2025
JAZZ
Product Launch
New Projects/Investments
- Jazz Pharmaceuticals will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting from November 19-23 in Honolulu, Hawaii.
- The presentations will feature clinical and preclinical research on Modeyso™ (dordaviprone) and new preclinical data for JZP3507 (formerly ONC206), reflecting the company's growing impact and innovation in neuro-oncology.
- Modeyso (dordaviprone) received accelerated approval in August 2025 from the U.S. Food and Drug Administration (FDA) for the treatment of H3 K27M-mutant diffuse midline glioma in adult and pediatric patients one year of age and older with progressive disease following prior therapy.
- The research aims to provide new insights into optimizing treatment for brain cancer, including characterizing potential molecular pathways associated with dordaviprone sensitivity and exploring its influence on the tumor immune environment.
Nov 11, 2025, 12:45 PM
Iambic Raises Over $100 Million in Oversubscribed Financing Round
JAZZ
New Projects/Investments
- Iambic, a clinical-stage life science and technology company, has successfully raised over $100 million in an oversubscribed financing round with support from new and existing investors.
- The company leverages an AI-driven discovery and development platform to develop novel medicines.
- This financing closely follows the presentation of clinical data for IAM1363 at the ESMO Congress and the announcement of a clinical collaboration with Jazz Pharmaceuticals.
- Iambic anticipates its KIF18A and CDK2/4 programs entering the clinic in the near term.
Nov 10, 2025, 1:00 PM
Quarterly earnings call transcripts for Jazz Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more